Skip to main content
Premium Trial:

Request an Annual Quote

EpiGenesis to Get $5 Million For Respiratory Drug Discovery


DURHAM, NC--New York investment firm Muzinich & Company arranged a private placement of $2.5 million, mostly from European institutional investors, with EpiGenesis Pharmaceuticals, a drug discovery company here focused on selective manipulation of gene expression to provide novel treatments for asthma and drug-resistant cancer. Based on the company's performance, the financing could expand to $5 million within two years.

"The company's proprietary drug discovery and target validation methods represent a leap in technology that can address many unmet medical needs," Muzinich principal Karen Giroux said.

The pharmaceutical plans to use the financing to advance development of its lead compound Epi 2010, and its technology platform for the asthmatic lung. EpiGenesis plans to form an alliance with a large multinational pharmaceutical company to complete preclinical and clinical evaluation of Epi 2010, according to President and CEO Jonathan Nyce.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.